186 related articles for article (PubMed ID: 32488251)
21. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Maragkos GA; Nelton EB; Richter S; Stippler M
World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488
[TBL] [Abstract][Full Text] [Related]
22. Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban.
Barzilai M; Kirgner I; Steimatzky A; Salzer Gotler D; Belnick Y; Shacham-Abulafia A; Avivi I; Raanani P; Yahalom V; Nakav S; Varon D; Yussim E; Bachar GN; Spectre G
Acta Haematol; 2020; 143(3):266-271. PubMed ID: 31610537
[TBL] [Abstract][Full Text] [Related]
23. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
[TBL] [Abstract][Full Text] [Related]
24. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
[TBL] [Abstract][Full Text] [Related]
25. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism.
Howe Z; Naville-Cook C; Cole D
J Thromb Thrombolysis; 2019 Feb; 47(2):280-286. PubMed ID: 30449001
[TBL] [Abstract][Full Text] [Related]
26. Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.
Monreal M
Thromb Haemost; 2018 Nov; 118(11):1850-1851. PubMed ID: 30332697
[No Abstract] [Full Text] [Related]
27. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
Sheikh-Taha M
Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
[TBL] [Abstract][Full Text] [Related]
28. [Monitoring of NOAC].
Zotz RB; Weißbach L
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):92-98. PubMed ID: 28083625
[TBL] [Abstract][Full Text] [Related]
29. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.
Wang TF; Zwicker JI; Ay C; Pabinger I; Falanga A; Antic D; Noble S; Khorana AA; Carrier M; Meyer G
J Thromb Haemost; 2019 Oct; 17(10):1772-1778. PubMed ID: 31353841
[No Abstract] [Full Text] [Related]
30. Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Lee S; White CM
Conn Med; 2012 Jan; 76(1):39-42. PubMed ID: 22372178
[No Abstract] [Full Text] [Related]
31. Andexanet alfa-The first 150 days.
Culbreth SE; Rimsans J; Sylvester K; Pallin DJ; Connors JM
Am J Hematol; 2019 Jan; 94(1):E21-E24. PubMed ID: 30358896
[No Abstract] [Full Text] [Related]
32. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
[TBL] [Abstract][Full Text] [Related]
33. Pharmacology and laboratory testing of the oral Xa inhibitors.
Samama MM; Meddahi S; Samama CM
Clin Lab Med; 2014 Sep; 34(3):503-17. PubMed ID: 25168939
[TBL] [Abstract][Full Text] [Related]
34. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Carrier M; Abou-Nassar K; Mallick R; Tagalakis V; Shivakumar S; Schattner A; Kuruvilla P; Hill D; Spadafora S; Marquis K; Trinkaus M; Tomiak A; Lee AYY; Gross PL; Lazo-Langner A; El-Maraghi R; Goss G; Le Gal G; Stewart D; Ramsay T; Rodger M; Witham D; Wells PS;
N Engl J Med; 2019 Feb; 380(8):711-719. PubMed ID: 30511879
[TBL] [Abstract][Full Text] [Related]
35. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
36. Quick reference guide to apixaban.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
[TBL] [Abstract][Full Text] [Related]
37. Thrombophilia testing in patients receiving rivaroxaban or apixaban for the treatment of venous thromboembolism.
Kovacs MR; Lazo-Langner A; Louzada ML; Kovacs MJ
Thromb Res; 2020 Nov; 195():231-232. PubMed ID: 32799129
[No Abstract] [Full Text] [Related]
38. Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.
Dreucean D; Nguyen SN; Donahue KR; Salazar E; Ruegger MC
J Thromb Thrombolysis; 2021 Jul; 52(1):161-169. PubMed ID: 33099722
[TBL] [Abstract][Full Text] [Related]
39. [Not Available].
Simeon L; Wuillemin WA
Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
[No Abstract] [Full Text] [Related]
40. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R
Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]